GLYX-13, a NMDA receptor glycine-site functional partial agonist, induces antidepressant-like effects without ketamine-like side effects

Neuropsychopharmacology

Volumn 38, Issue 5, 2013, Pages 729-742

  Burgdorf, Jeffrey ^a   Zhang, Xiao Lei ^b   Nicholson, Katherine L ^c   Balster, Robert L ^c   David Leander, J ^a   Stanton, Patric K ^b   Gross, Amanda L ^a   Kroes, Roger A ^a   Moskal, Joseph R ^a  

^a Northwestern University   (United States)

^b NEW YORK MEDICAL COLLEGE   (United States)

^c VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

depression; GLYX 13; ketamine; medial prefrontal cortex; NMDA receptor

Indexed keywords

6 NITRO 7 SULFAMOYLBENZO[F]QUINOXALINE 2,3 DIONE; ALPHA AMINO 3 HYDROXY 5 METHYL 4 ISOXAZOLEPROPIONIC ACID; GLYX 13; KAINIC ACID RECEPTOR; KETAMINE; MESSENGER RNA; N METHYL DEXTRO ASPARTIC ACID RECEPTOR STIMULATING AGENT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIDEPRESSANT ACTIVITY; ARTICLE; EXCITATORY POSTSYNAPTIC POTENTIAL; HIPPOCAMPAL CA1 REGION; HYPOPHAGIA; IN VITRO STUDY; MALE; MICROARRAY ANALYSIS; NONHUMAN; NUCLEOTIDE SEQUENCE; OPEN FIELD TEST; PLACE PREFERENCE; POLYACRYLAMIDE GEL ELECTROPHORESIS; PREFRONTAL CORTEX; PREPULSE INHIBITION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEDATION; SYNAPSE; SYNAPTIC TRANSMISSION;

ACOUSTIC STIMULATION; ACTION POTENTIALS; ANIMALS; ANTIDEPRESSIVE AGENTS; BRAIN; CONDITIONING, OPERANT; DEPRESSION; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; EXCITATORY AMINO ACID AGONISTS; EXCITATORY AMINO ACID ANTAGONISTS; EXPLORATORY BEHAVIOR; FLUOXETINE; GENE EXPRESSION PROFILING; KETAMINE; LONG-TERM POTENTIATION; MALE; OLIGOPEPTIDES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, GLUTAMATE; STARTLE REACTION; SWIMMING;

EID: 84875222862     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/npp.2012.246     Document Type: Article

References (61)

1. Aanhet Rot M, Collins KA, Murrough JW, Perez AM, Reich DL, Charney DS et al (2010) Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression. Biol Psychiatry, 67, 139-145.
2. Abraham WC (2008). Metaplasticity: tuning synapses and networks for plasticity. Nat Rev Neurosci 9: 387-399.
3. Autry AE, Adachi M, Nosyreva E, Na ES, Los MF, Cheng PF et al (2011). NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses. Nature 475: 91-95.
4. Berman RM, Cappiello A, Anand A, Oren DA, Heninger GR, Charney DS et al (2000). Antidepressant effects of ketamine in depressed patients. Biol Psychiatry 47: 351-354.
5. Bisaga A, Evans SM (2004). Acute effects of memantine in combination with alcohol in moderate drinkers. Psychopharmacology (Berl) 172: 16-24.
6. Bodnoff SR, Suranyi-Cadotte B, Quirion R, Meaney MJ (1989). A comparison of the effects of diazepam versus several typical and atypical anti-depressant drugs in an animal model of anxiety. Psychopharmacology (Berl) 97: 277-279.
7. Burgdorf J, Knutson B, Panksepp J, Ikemoto S (2001a). Nucleus accumbens amphetamine microinjections unconditionally elicit 50-kHz ultrasonic vocalizations in rats. Behav Neurosci 115: 940-944.
8. Burgdorf J, Knutson B, Panksepp J, Shippenberg TS (2001b). Evaluation of rat ultrasonic vocalizations as predictors of the conditioned aversive effects of drugs. Psychopharmacology (Berl) 155: 35-42.
9. Burgdorf J, Wood PL, Kroes RA, Moskal JR, Panksepp J (2007). Neurobiology of 50-kHz ultrasonic vocalizations in rats: electrode mapping, lesion, and pharmacology studies. Behav Brain Res 182: 274-283.
10. Burgdorf J, Panksepp J, Brudzynski SM, Beinfeld MC, Cromwell HC, Kroes RA et al (2009). The effects of selective breeding for differential rates of 50-kHz ultrasonic vocalizations on emotional behavior in rats. Dev Psychobiol 51: 34-46.
11. Burgdorf J, Kroes RA, Beinfeld MC, Panksepp J, Moskal JR (2010). Uncovering the molecular basis of positive affect using roughand-tumble play in rats: a role for insulin-like growth factor I. Neuroscience 168: 769-777.
12. Burgdorf J, Kroes RA, Weiss C, Oh MM, Disterhoft JF, Brudzynski SM et al (2011a). Positive emotional learning is regulated in the medial prefrontal cortex by GluN2B-containing NMDA receptors. Neuroscience 192: 515-523.
13. Burgdorf J, Zhang XL, Weiss C, Matthews E, Disterhoft JF, Stanton PK et al (2011b). The N-methyl-d-aspartate receptor modulator GLYX-13 enhances learning and memory, in young adult and learning impaired aging rats. Neurobiol Aging 32: 698-706.
14. Danysz W, Parsons CG (1998). Glycine and N-methyl-D-aspartate receptors: physiological significance and possible therapeutic applications. Pharmacol Rev 50: 597-664.
15. de Bruin NM, Ellenbroek BA, Cools AR, Coenen AM, van Luijtelaar EL (1999). Differential effects of ketamine on gating of auditory evoked potentials and prepulse inhibition in rats. Psychopharmacology (Berl) 142: 9-17.
16. Detke MJ, Rickels M, Lucki I (1995). Active behaviors in the rat forced swimming test differentially produced by serotonergic and noradrenergic antidepressants. Psychopharmacology 121: 66-72.
17. Diazgranados N, Ibrahim L, Brutsche NE, Newberg A, Kronstein P, Khalife S et al (2010a). A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression. Arch Gen Psychiatry 67: 793-802.
18. Diazgranados N, Ibrahim LA, Brutsche NE, Ameli R, Henter ID, Luckenbaugh DA et al (2010b). Rapid resolution of suicidal ideation after a single infusion of an N-methyl-D-aspartate antagonist in patients with treatment-resistant major depressive disorder. J Clin Psychiatry 71: 1605-1611.
19. Dulawa SC, Hen R (2005). Recent advances in animal models of chronic antidepressant effects: the novelty-induced hypophagia test. Neurosci Biobehav Rev 29: 771-783.
20. Feyissa AM, Chandran A, Stockmeier CA, Karolewicz B (2009). Reduced levels of NR2A and NR2B subunits of NMDA receptor and PSD-95 in the prefrontal cortex in major depression. Prog Neuropsychopharmacol Biol Psychiatry 33: 70-75.
21. Goff DC, Tsai G, Levitt J, Amico E, Manoach D, Schoenfeld DA et al (1999). A placebo-controlled trial of D-cycloserine added to conventional neuroleptics in patients with schizophrenia. Arch Gen Psychiatry 56: 21-27.
22. Goulart BK, de Lima MN, de Farias CB, Reolon GK, Almeida VR, Quevedo J et al (2011). Ketamine impairs recognition memory consolidation and prevents learning-induced increase in hippocampal brain-derived neurotrophic factor levels. Neuroscience 167: 969-973.
23. Gozes I, Giladi E, Pinhasov A, Bardea A, Brenneman DE (2000). Activity-dependent neurotrophic factor: intranasal administration of femtomolar-acting peptides improve performance in a water maze. J Pharmacol Exp Ther 293: 1091-1098.
24. Haring R, Stanton PK, Scheideler MA, Moskal JR (1991). Glycinelike modulation of N-methyl-D-aspartate receptors by a monoclonal antibody that enhances long-term potentiation. J Neurochem 57: 323-332.
25. Heresco-Levy U, Ermilov M, Shimoni J, Shapira B, Silipo G, Javitt DC (2002a). Placebo-controlled trial of D-cycloserine added to conventional neuroleptics, olanzapine, or risperidone in schizophrenia. Am J Psychiatry 159: 480-482.
26. Heresco-Levy U, Kremer I, Javitt DC, Goichman R, Reshef A, Blanaru M et al (2002b). Pilot-controlled trial of D-cycloserine for the treatment of post-traumatic stress disorder. Int J Neuropsychopharmacol 5: 301-307.
27. Heresco-Levy U, Javitt DC, Gelfin Y, Gorelik E, Bar M, Blanaru M et al (2006). Controlled trial of D-cycloserine adjuvant therapy for treatment-resistant major depressive disorder. J Affect Disord 93: 239-243.
28. Huang YY, Colino A, Selig DK, Malenka RC (1992). The influence of prior synaptic activity on the induction of long-term potentiation. Science 255: 730-733.
29. Kessler RC, Chiu WT, Demler O, Merikangas KR, Walters EE (2005). Prevalence, severity, and comorbidity of 12-month DSMIV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 62: 617-627.
30. Kew JN, Kemp JA (1998). An allosteric interaction between the NMDA receptor polyamine and ifenprodil sites in rat cultured cortical neurones. J Physiol 512(Pt 1): 17-28.
31. Kroes RA, Panksepp J, Burgdorf J, Otto NJ, Moskal JR (2006). Modeling depression: social dominance-submission gene expression patterns in rat neocortex. Neuroscience 137: 37-49.
32. Langer G, Karazman R, Neumark J, Saletu B, Schönbeck G, Grünberger J et al (1995). Isoflurane narcotherapy in depressive patients refractory to conventional antidepressant drug treatment. A double-blind comparison with electroconvulsive treatment. Neuropsychobiology 31: 182-194.
33. Lee HK, Barbarosie M, Kameyama K, Bear MF, Huganir RL (2000). Regulation of distinct AMPA receptor phosphorylation sites during bidirectional synaptic plasticity. Nature 405: 955-959.
34. Li N, Lee B, Liu RJ, Banasr M, Dwyer JM, Iwata M et al (2010). mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science 329: 959-964.
35. Machado-Vieira R, Manji HK, Zarate CA (2009). The role of the tripartite glutamatergic synapse in the pathophysiology and therapeutics of mood disorders. Neuroscientist 15: 525-539.
36. Maeng S, Zarate CA Jr., Du J, Schloesser RJ, McCammon J, Chen G et al (2008). Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors. Biol Psychiatry 63: 349-352.
37. Malinow R, Malenka RC (2002). AMPA receptor trafficking and synaptic plasticity. Annu Rev Neurosci 25: 103-126.
38. Mathers CD, Loncar D (2006). Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med 3: e442.
39. McShane R, Areosa Sastre A, Minakaran N (2006). Memantine for dementia. Cochrane Database Syst Rev CD003154.
40. Moskal JR, Kuo AG, Weiss C, Wood PL, O'Connor Hanson A, Kelso S et al (2005). GLYX-13: a monoclonal antibody-derived peptide that acts as an N-methyl-D-aspartate receptor modulator. Neuropharmacology 49: 1077-1087.
41. Nicholson KL, Balster RL (2009). The discriminative stimulus effects of N-methyl-D-aspartate glycine-site ligands in NMDA antagonist-trained rats. Psychopharmacology (Berl) 203: 441-451.
42. Nong Y, Huang YQ, Ju W, Kalia LV, Ahmadian G, Wang YT et al (2003). Glycine binding primes NMDA receptor internalization. Nature 422: 302-307.
43. Oldendorf WH (1970). Measurement of brain uptake of radiolabeled substances using a tritiated water internal standard. Brain Res 24: 372-376.
44. Page ME, Detke MJ, Dalvi A, Kirby LG, Lucki I (1999). Serotonergic mediation of the effects of fluoxetine, but not desipramine, in the rat forced swimming test. Psychopharmacology (Berl) 147: 162-167.
45. Price RB, Nock MK, Charney DS, Mathew SJ (2009). Effects of intravenous ketamine on explicit and implicit measures of suicidality in treatment-resistant depression. Biol Psychiatry 66: 522-526.
46. Rofael HZ, Abdel-Rahman MS (2002). The role of ketamine on plasma cocaine pharmacokinetics in rat. Toxicol Lett 129: 167-176.
47. Skolnick P, Layer RT, Popik P, Nowak G, Paul IA, Trullas R (1996). Adaptation of N-methyl-D-aspartate (NMDA) receptors following antidepressant treatment: implications for the pharmacotherapy of depression. Pharmacopsychiatry 29: 23-26.
48. Skolnick P, Popik P, Trullas R (2009). Glutamate-based antidepressants: 20 years on. Trends Pharmacol Sci 30: 563-569.
49. Song I, Huganir RL (2002). Regulation of AMPA receptors during synaptic plasticity. Trends Neurosci 25: 578-588.
50. Stanton PK, Potter PE, Aguilar J, Decandia M, Moskal JR (2009). Neuroprotection by a novel NMDAR functional glycine site partial agonist, GLYX-13. Neuroreport 20: 1193-1197.
51. Stringer JL, Greenfield LJ, Hackett JT, Guyenet PG (1983). Blockade of long-term potentiation by phencyclidine and sigma opiates in the hippocampus in vivo and in vitro. Brain Res 280: 127-138.
52. Thompson LT, Moskal JR, Disterhoft JF (1992). Hippocampusdependent learning facilitated by a monoclonal antibody or D-cycloserine. Nature 359: 638-641.
53. Traynelis SF, Wollmuth LP, McBain CJ, Menniti FS, Vance KM, Ogden KK et al (2010). Glutamate receptor ion channels: structure, regulation, and function. Pharmacol Rev 62: 405-496.
54. Van Gelder RN, von Zastrow ME, Yool A, Dement WC, Barchas JD, Eberwine JH (1990). Amplified RNA synthesized from limited quantities of heterogeneous cDNA. Proc Natl Acad Sci USA 87: 1663-1667.
55. Wesierska M, Macias-Gonzalez R, Bures J (1990). Differential effect of ketamine on the reference and working memory versions of the Morris water maze task. Behav Neurosci 104: 74-83.
56. Wood PL, Mahmood SA, Moskal JR (2008). Antinociceptive action of GLYX-13: an N-methyl-D-aspartate receptor glycine site partial agonist. Neuroreport 19: 1059-1061.
57. Yang Q, Liao ZH, Xiao YX, Lin QS, Zhu YS, Li ST (2011). Hippocampal synaptic metaplasticity requires the activation of NR2B-containing NMDA receptors. Brain Res Bull 84: 137-143.
58. Zarate CA Jr., Singh JB, Carlson PJ, Brutsche NE, Ameli R, Luckenbaugh DA et al (2006a). A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry 63: 856-864.
59. Zarate CA Jr., Singh JB, Quiroz JA, De Jesus G, Denicoff KK, Luckenbaugh DA et al (2006b). A double-blind, placebocontrolled study of memantine in the treatment of major depression. Am J Psychiatry 163: 153-155.
60. Zarate CA Jr., Brutsche NE, Ibrahim L, Franco-Chaves J, Diazgranados N, Cravchik A et al (2012). Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trial. Biol Psychiatry 71: 939-946.
61. Zhang XL, Sullivan JA, Moskal JR, Stanton PK (2008). A NMDA receptor glycine site partial agonist, GLYX-13, simultaneously enhances LTP and reduces LTD at Schaffer collateral-CA1 synapses in hippocampus. Neuropharmacology 55: 1238-1250.